Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2

Status

Unknown 3Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 7Observational 3

Sponsor

Cancer Type

Gastrointestinal 92Thoracic 49Head & Neck 27Other solid neoplasm 16Breast 15Genitourinary 14Dermatologic 14Lymphoid 8Gynecologic 8Tumor-Agnostic 7Sarcoma 7Other hematologic neoplasm 6CNS 4Plasma cell 1Myeloid 1

Conditions

Neoplasms 5Neoplasm Metastasis 3

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Immune Checkpoint Inhibitors × Tumor-Agnostic × Clear all
NCT06524570 2026-02-18

iFOCUS

UMC Utrecht

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT07142200 2025-08-26

DECIDING

RenJi Hospital

Phase 2 Not yet recruiting
45 enrolled
Tumor-Agnostic

Neoplasms

NCT06076135 2025-06-15

ILDR-01

Shantou University Medical College

Phase 2 Active not recruiting
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06047860 2023-09-21

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT03790488 2023-07-03

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

Jounce Therapeutics, Inc.

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

NCT05790447 2023-03-30

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
60 enrolled
Tumor-Agnostic

Neoplasms

NCT05530200 2022-09-07

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
56 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡